Literature DB >> 23836253

[Dyspnoea, cough and B symptoms in a 40-year-old woman].

A Wolfensberger1, R Benz, E W Russi, M Tinguely, C Keller, B Gerber.   

Abstract

Multicentric Castleman's disease (MCD) is a rare polyclonal lymphoproliferative disorder that is typically accompanied by an overproduction of circulating cytokines (mainly interleukin-6). We here report the case of a 40-year-old HIV-negative woman with pulmonary manifestation of MCD. There is no standard treatment for MCD. In our patient, various treatment courses with immunomodulatory drugs were unsuccessful. Finally, treatment with the interleukin-6 receptor antibody tocilizumab has resulted in continual clinical improvement over the last 5 years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23836253     DOI: 10.1007/s00108-013-3327-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  15 in total

Review 1.  Castleman disease.

Authors:  Angela Dispenzieri
Journal:  Cancer Treat Res       Date:  2008

2.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.

Authors:  K Yoshizaki; T Matsuda; N Nishimoto; T Kuritani; L Taeho; K Aozasa; T Nakahata; H Kawai; H Tagoh; T Komori
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

3.  How I treat HIV-associated multicentric Castleman disease.

Authors:  Mark Bower
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

4.  Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.

Authors:  Frits van Rhee; Katie Stone; Susann Szmania; Bart Barlogie; Zeba Singh
Journal:  Clin Adv Hematol Oncol       Date:  2010-07

Review 5.  Castleman's disease--a two compartment model of HHV8 infection.

Authors:  Klaus-Martin Schulte; Nadia Talat
Journal:  Nat Rev Clin Oncol       Date:  2010-07-06       Impact factor: 66.675

6.  Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease.

Authors:  Christian Hoffmann; Holger Schmid; Markus Müller; Christian Teutsch; Jan van Lunzen; Stefan Esser; Timo Wolf; Christoph Wyen; Michael Sabranski; Heinz-August Horst; Stefan Reuter; Martin Vogel; Hans Jäger; Johannes Bogner; Keikawus Arasteh
Journal:  Blood       Date:  2011-07-21       Impact factor: 22.113

7.  Human herpesvirus 8-related Castleman disease in the absence of HIV infection.

Authors:  A Dossier; V Meignin; C Fieschi; D Boutboul; E Oksenhendler; L Galicier
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

8.  Interleukin-6 gene expression in Castleman's disease.

Authors:  M B Leger-Ravet; M Peuchmaur; O Devergne; J Audouin; M Raphael; J Van Damme; P Galanaud; J Diebold; D Emilie
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

9.  Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.

Authors:  Laurence Gérard; Alice Bérezné; Lionel Galicier; Véronique Meignin; Martine Obadia; Nathalie De Castro; Christine Jacomet; Renaud Verdon; Isabelle Madelaine-Chambrin; Emmanuelle Boulanger; Sylvie Chevret; Felix Agbalika; Eric Oksenhendler
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

10.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.